Some psoriasis patients respond inadequately to monotherapy and require combination therapy. Combining a biologic and nonbiologic agent may provide improvement.
Objective
To review the efficacy and safety of combination treatment with biologic and nonbiologic agents in the treatment of moderate to severe plaque psoriasis.
Methods
We searched Pubmed for English-language publications evaluating combination treatment with biologic and nonbiologic therapies through June 2014.
Results
Etancercept was the most commonly used biologic followed by ustekinumab, adalimumab, and infliximab. The majority of nonbiologic therapies reported were narrowband UVB (NBUVB) and methotrexate. Most cases reported increased efficacy with combination therapy with serious adverse events occurring in less than 3% of patients.
Conclusion
Combination biologic plus nonbiologic therapy, especially NBUVB with biologics is a viable clinical strategy in the treatment of psoriasis patients unresponsive to monotherapy, despite limitations in the data available. However, the long-term impact of these combinations has yet to be determined.
GottliebA.B., LangleyR.G., StroberB.E.A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol.2012; 167(3): 649–657.
6.
ZachariaeC., MorkN.J., ReunalaT.The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol.2008; 88(5): 495–501.
7.
DriessenR.J., van de KerkhofP.C., de JongE.M.Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol.2008; 159(2): 460–463.
8.
YamauchiP.S., LoweN.J.Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int J Dermatol.2008; 47(2): 202–204.
9.
PaulC., PuigL., KragballeK.Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol.2014; 170(2): 425–434.
10.
van den ReekJ.M., van LumigP.P., KievitW.Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat.2013; 24(5): 361–368.
11.
GladmanD.D., MeaseP.J., RitchlinC.T.Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum.2007; 56(2): 476–488.
12.
WeeJ.S., PetrofG., JacksonK., BarkerJ.N., SmithC.H.Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol.2012; 167(2): 411–416.
13.
StroberB.E., ClarkeS.Etanercept for the treatment of psoriasis: combination therapy with other modalities. J Drugs Dermatol.2004; 3(3): 270–272.
14.
DalakerM., BonesronningJ.H.Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol.2009; 23(3): 277–282.
15.
GisondiP., Del GiglioM., CotenaC., GirolomoniG.Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol.2008; 158(6): 1345–1349.
16.
ConleyJ., NantonJ., DhawanS., PearceD.J., FeldmanS.R.Novel combination regimens: biologics and acitretin for the treatment of psoriasis — a case series. J Dermatolog Treat.2006; 17(2): 86–89.
17.
SmithE.C., RiddleC., MenterM.A., LebwohlM.Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol.2008; 47(5): 514–518.
18.
PhilippS., Wilsmann-TheisD., WeyergrafA.Combination of adalimumab with traditional systemic antipsoriatic drugs — a report of 39 cases. J Dtsch Dermatol Ges.2012; 10(11): 821–837.
19.
HeineckeG.M., LuberA.J., LevittJ.O., LebwohlM.G.Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol.2013; 12(10): 1098–1102.
20.
IyerS., YamauchiP., LoweN.J.Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol.2002; 146(1): 118–121.
21.
LeeE.J., ShinM.K., KimN.I.A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol.2010; 22(2): 138–142.
22.
YamauchiP.S., LoweN.J.Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol.2006; 54(3 Suppl 2): S135–138.
23.
De SimoneC., D'AgostinoM., CapizziR., CapponiA., VenierA., CaldarolaG.Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol.2011; 21(4): 568–572.
24.
KircikL., BagelJ., KormanN.Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol.2008; 7(3): 245–253.
25.
WolfP., HoferA., LegatF.J.Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol.2009; 160(1): 186–189.
26.
LyndeC.W., GuptaA.K., GuentherL., PoulinY., LevesqueA., BissonnetteR.A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatolog Treat.2012; 23(4): 261–267.
27.
GambichlerT., TiggesC., ScolaN.Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol.2011; 164(6): 1383–1386.
28.
Calzavara-PintonP.G., SalaR., ArisiM., RossiM.T., VenturiniM., OrtelB.Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Br J Dermatol.2013; 169(1): 130–136.
29.
WolfP., WegerW., LegatF.J.Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol.2012; 166(1): 147–153.
ParkK.K., WuJ.J., KooJ.A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol.2013; 27(7): 899–906.
32.
ThaciD., OrtonneJ.P., ChimentiS.A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol.2010; 163(2): 402–411.
33.
LebwohlM.G., KircikL., Callis DuffinK.A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol.2013; 69(3): 385–392.
34.
CampioneE., MazzottaA., PaternoE.J., DiluvioL., PrinzJ.C., ChimentiS.Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol.2009; 89(3): 288–291.
35.
StrohalR., PuigL., ChouelaE.The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat.2013; 24(3): 169–178.
36.
PaulC.F., HoV.C., McGeownC.Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol.2003; 120(2): 211–216.
37.
PatelR.V., ClarkL.N., LebwohlM., WeinbergJ.M.Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol.2009; 60(6): 1001–1017.
38.
BlackR.J., GavinA.T.Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data. Br J Dermatol.2006; 154(3): 566–567.
39.
LeeE., KooJ., BergerT.UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol.2005; 44(5): 355–360.
40.
HearnR.M., KerrA.C., RahimK.F., FergusonJ., DaweR.S.Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol.2008; 159(4): 931–935.
